LipoScience to Release Second Quarter Fiscal Year 2013 Financial Results

        Print
| Source: LipoScience, Inc.

RALEIGH, N.C., July 23, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its second quarter of fiscal year 2013 financial results before the market open on Tuesday, August 6, 2013. An investor conference call will follow on the same day at 8:30 A.M. ET.

The conference call will be hosted by Richard Brajer, President and Chief Executive Officer, and Lucy Martindale, Executive Vice President and Chief Financial Officer.

To participate in the call, please dial (877) 303-2523 (U.S. and Canada) or (253) 237-1755 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://investor.liposcience.com.

A replay of the conference call will be available beginning August 6, 2013 at 11:30 A.M. ET and ending on August 18, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 23455013. A replay of the webcast will be available on the corporate website for two weeks.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Investor Relations
ICR, Inc.
Bob Yedid
Senior Vice President
646-277-1250


LipoScience, Inc.
Tori Hall

(919) 256-1046